Cancer treatment and research communications最新文献

{"title":"Prognostic impact of residual viable tumor percentage on non-small cell lung cancer recurrence after neoadjuvant immunochemotherapy.","authors":"Ruihe Liu, Shenhua Liang, Jiayuan Tian, Yitao Yang, Xingyu Luo, Guowei Ma","doi":"10.1016/j.ctarc.2026.101462","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101462","url":null,"abstract":"<p><strong>Background: </strong>Recent clinical trials have identified the percentage of residual viable tumor (%RVT) following neoadjuvant immunochemotherapy as a prognostic risk factor for patients with non-small cell lung cancer (NSCLC). This study aimed to identify the significance of %RVT concerning the patterns of postoperative recurrence.</p><p><strong>Methods: </strong>This retrospective study involved 339 patients diagnosed with NSCLC who underwent neoadjuvant immunochemotherapy followed by radical surgical intervention. The optimal cutoff value of %RVT was identified as a continuous covariate for recurrence-free survival (RFS) using the rolr R package.</p><p><strong>Results: </strong>In our cohort, the estimated optimal cutoffs for %RVT were identified as 5% and 30%. Patients with >30% RVT exhibited significantly worse RFS compared to those with 6-30% RVT (P = 0.026) and those with ≤5% RVT (P < 0.001). The overall recurrence rate (≤5% RVT, 12.2%; 6-30% RVT, 29.4%; >30% RVT, 37.1%; P < 0.001) and distant recurrence rate (≤5% RVT, 2.7%; 6-30% RVT, 16.7%; >30% RVT, 24.7%; P < 0.001) increased progressively with advancing %RVT. Cox regression analyses revealed that %RVT, visceral pleural infiltration, lymphovascular infiltration, and pN stage were independent risk factors for RFS. Based on these identified factors, a nomogram model was subsequently developed, yielding a corrected C-index of 0.701 through bootstrap analysis.</p><p><strong>Conclusions: </strong>We identified %RVT in post-treatment tumor lesions as a significant risk factor for the recurrence of NSCLC following neoadjuvant immunochemotherapy and surgery, with optimal cutoffs established at 5% and 30%. Furthermore, an increase in %RVT may have a more pronounced effect on distant recurrence.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"49 ","pages":"101462"},"PeriodicalIF":3.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of neoadjuvant radiotherapy with 10-year survival outcomes in large cell lung cancer: A retrospective SEER-based study.","authors":"Yang Zhang, Lang Su, Yuchen Chang, Yanli Cai, Kelin Hong","doi":"10.1016/j.ctarc.2026.101359","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101359","url":null,"abstract":"<p><strong>Background: </strong>Large cell lung cancer (LCLC) is a distinct subtype of non-small cell lung cancer. Optimizing its treatment is crucial for improving prognosis. Radiotherapy plays an important adjuvant role, yet long-term efficacy data specific to LCLC are limited, and comparisons between neoadjuvant and adjuvant radiotherapy are scarce.</p><p><strong>Methods: </strong>This study evaluated radiotherapy effectiveness in LCLC and compared survival outcomes between neoadjuvant radiotherapy and adjuvant radiotherapy. Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. After propensity score matching, neoadjuvant and adjuvant radiotherapy cohorts were established. Statistical analyses included survival curves, univariate and multivariate analyses, subgroup analysis, and multiple regression.</p><p><strong>Results: </strong>The neoadjuvant radiotherapy group showed significantly better overall survival (OS) (P = 0.019) and cancer-specific survival (CSS) (P = 0.036) compared to the adjuvant radiotherapy group. Multivariate regression revealed that, relative to the neoadjuvant group, adjuvant radiotherapy group had increased hazard ratios for OS (HR: 1.2 [1.0-1.4], P = 0.043) and CSS (HR: 1.2 [1.0-1.4], P = 0.036).</p><p><strong>Conclusions: </strong>Neoadjuvant radiotherapy was associated with improved 10-year survival and may represent a valuable treatment option for patients with LCLC. Further prospective studies are needed to validate these findings.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"49 ","pages":"101359"},"PeriodicalIF":3.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of Node-RADS in predicting lymph node metastasis in endometrial cancer.","authors":"Fatemeh Shakki Katouli, Fahimeh Zeinalkhani, Mohammad Hossein Hashemi, Fatemeh Nili, Rana Karimi, Reihaneh Mortazavi Ardestani, Elahe Basami, Shahrzad Sepidbar, Mahrooz Malek, Mohammadreza Tahamtan","doi":"10.1016/j.ctarc.2026.101464","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101464","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate assessment of lymph node (LN) status is essential for staging of endometrial cancer (EC). This study evaluated the diagnostic performance of the Node Reporting and Data System (Node-RADS) in predicting pelvic LN metastasis in EC using preoperative MRI.</p><p><strong>Methods: </strong>In this retrospective study, patients with pathologically confirmed EC who underwent preoperative pelvic MRI between June 2020 and September 2025 were included. Node-RADS scores were assigned independently by two gynecologic radiologists in consensus and were correlated with surgical pathology. Diagnostic performance was assessed using receiver operating characteristic analysis. Area under the curve (AUC) values were compared using the DeLong test. Logistic regression was applied to identify independent predictors of LN metastasis.</p><p><strong>Results: </strong>Among 169 lymph nodes in 72 patients, 21 (12.4%) were metastatic. Metastatic nodes demonstrated significantly higher Node-RADS scores and larger short-axis diameters (p < 0.05). Node-RADS was the strongest predictor of metastatic involvement (OR = 264, 95% CI: 16-41,330; p < 0.0001). Tumor ADC values independently correlated with nodal metastasis (OR = 0.984, 95% CI: 0.966-0.996; p = 0.005). Node-RADS demonstrated excellent diagnostic accuracy (AUC = 0.963; 95% CI: 0.910-1.000), significantly outperforming size-based assessment (AUC = 0.851; p = 0.0029). Using a cutoff of Node-RADS ≥ 3 yielded optimal performance, with a sensitivity of 85.7% and specificity of 98.0%. Increasing the cutoff to ≥ 4 achieved perfect specificity (100%) at the cost of reduced sensitivity (47.6%).</p><p><strong>Conclusion: </strong>MRI-based Node-RADS is a robust and highly accurate tool for predicting pelvic LN metastasis in EC, outperforming conventional size criteria and providing strong independent diagnostic value.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"49 ","pages":"101464"},"PeriodicalIF":3.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the flask: cancer cell lines and the limits of biological extrapolation.","authors":"Saeed Aghebat-Bekheir, Armin Salek-Maghsoudi, Ali Mohammad Alizadeh, Mohammad Abdollahi","doi":"10.1016/j.ctarc.2026.101470","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101470","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer cell lines remain central to cancer biology, drug screening, molecular pharmacology, and mechanistic research because they are accessible and experimentally manageable. Their routine use, however, can blur an important distinction between what a model demonstrates directly and what can reasonably be inferred from it. This Editorial examines that boundary and considers how cancer cell lines should be matched to the biological question being asked.</p><p><strong>Current concept: </strong>Authentication, mycoplasma testing, and careful documentation of culture conditions are essential components of technical validity, but they do not, by themselves, establish biological relevance. A cancer-derived cell line may be entirely appropriate for a focused mechanistic question while providing a much weaker basis for claims about normal tissue physiology, systemic toxicity, tumor-microenvironment interactions, or clinical response. The central issue is therefore not whether cancer cell lines should be used, but whether the model, the research question, and the intended level of inference are aligned.</p><p><strong>Conclusion: </strong>Cancer cell lines should remain part of the experimental toolkit, but the limits of the evidence they provide need to be stated more clearly. Broader biological or translational claims require broader support from complementary models when the question demands it. Model selection should therefore be driven by the question under study, and conclusions should remain proportionate to what the experimental system can actually support.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"101470"},"PeriodicalIF":3.5,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Tumor-microbe transkingdom interactions in cancers at body interfaces: mechanisms of neutrophil lifespan extension and functional reprogramming with therapeutic implications [Cancer Treatment and Research Communications 46 (2026) 101065].","authors":"I Mohamed, S Lohse","doi":"10.1016/j.ctarc.2026.101415","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101415","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"101415"},"PeriodicalIF":3.5,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].","authors":"Paolo Bironzo, Alessandro Morabito, Sonia Silipigni, Vincenzo Adamo, Enrica Capelletto, Sabrina Rossi, Marcello Tiseo, Michele Montrone, Ivan Facilissimo, Gianpiero Romano, Luna Chiara Masini, Giovanni Luca Ceresoli, Cesare Gridelli, Antonio Lugini, Sara Pilotto, Pierosandro Tagliaferri, Emilio Bria, Diego Cortinovis, Erika Rijavec, Paolo Borghetti, Matteo Brighenti, Anna Maria Carta, Libero Ciuffreda, Raffaele Giusti, Marianna Macerelli, Francesco Verderame, Francesca Zanelli, Rossana Berardi, Vanesa Gregorc, Concetta Sergi, Emanuela Vattemi, Roberto Ferrara, Pier Luigi Piovano, Lorenzo Livi, Gloria Borra, Stefania Gori, Michele Aieta, Alessandro Bertolini, Fabiana Letizia Cecere, Giulia Pasello, Danilo Rocco, Giuseppe Lo Certo, Livia Marrone, Lucia Simoni, Barbara Roncari, Silvia Novello, Sara Ramella","doi":"10.1016/j.ctarc.2026.101350","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101350","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"101350"},"PeriodicalIF":3.5,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of delayed postoperative radiation therapy in breast cancer patients undergoing neoadjuvant chemotherapy: A subanalysis of the AMAZONA III prospective cohort","authors":"Júlio César Prestes ,&nbsp;Gustavo Viani ,&nbsp;Andre Guimaraes Gouveia ,&nbsp;Maurício Fraga da Silva ,&nbsp;Fabio Ynoe. Moraes ,&nbsp;Daniela Dornelles Rosa ,&nbsp;Carlos Henrique Escosteguy Barrios ,&nbsp;Gustavo Werutsky ,&nbsp;Jose Bines ,&nbsp;Eduardo Henrique Cronemberger Costa e Silva ,&nbsp;Geraldo Silva Queiroz ,&nbsp;Fabiana Baroni Makdissi ,&nbsp;Vladmir Cordeiro de Lima ,&nbsp;Ruffo Freitas-Junior ,&nbsp;José d'Oliveira Couto Filho ,&nbsp;Karla Emerenciano ,&nbsp;Heloisa Magda Resende ,&nbsp;Susanne Crocamo ,&nbsp;Tomas Reinert ,&nbsp;Brigitte Van Eyll ,&nbsp;Gustavo Nader Marta","doi":"10.1016/j.ctarc.2026.101119","DOIUrl":"10.1016/j.ctarc.2026.101119","url":null,"abstract":"<div><h3>Background</h3><div>Delays in starting postoperative radiation therapy (PORT) in breast cancer patients may be associated with poorer clinical outcomes. This analysis aimed to identify factors contributing to delayed PORT in patients with breast cancer who underwent neoadjuvant chemotherapy followed by surgery and PORT in a Brazilian cohort.</div></div><div><h3>Methods</h3><div>Participants were categorized based on the interval from surgery to the initiation of PORT into two groups: ≤ 8 weeks and &gt; 8 weeks. Socioeconomic and clinicopathological factors were analyzed for associations with delayed PORT. Univariable and multivariable regressions were performed.</div></div><div><h3>Results</h3><div>Factors significantly associated with delayed PORT included low educational level (RR: 1.50; 95 % CI: 1.05–2.14; <em>p</em> = 0.0276), public health insurance (RR: 3.29; 95 % CI: 1.76–6.12; <em>p</em> = 0.0002) and having a Luminal A or Luminal B-HER2-negative subtype (RR: 1.92; 95 % CI: 1.14–3.23; <em>p</em> = 0.0153) compared to the Triple Negative subtype. The absence of adjuvant endocrine therapy was associated with a lower risk of delayed PORT (RR: 0.67; 95 % CI: 0.46–0.99; <em>p</em> = 0.0338). In the multivariate analysis, public health insurance remained the sole independent predictor of delayed PORT (RR: 2.98; 95 % CI: 1.60–5.55; <em>p</em> = 0.0006).</div></div><div><h3>Conclusion</h3><div>In this cohort, reliance on public health insurance emerged as the primary independent predictor of delayed initiation of PORT in breast cancer patients who received neoadjuvant chemotherapy. Lower educational levels and household income also contributed to delays, highlighting disparities within the healthcare system. Addressing these barriers is essential for improving timely access to PORT and potentially enhancing clinical outcomes in this population.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101119"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis","authors":"Tânia Rodrigues ,&nbsp;Joana Albuquerque ,&nbsp;Joana Cardoso ,&nbsp;Ivo Sousa-Ferreira ,&nbsp;João Paulo Martins ,&nbsp;José Luís Passos Coelho","doi":"10.1016/j.ctarc.2025.101091","DOIUrl":"10.1016/j.ctarc.2025.101091","url":null,"abstract":"<div><h3>Purpose</h3><div>The prognostic value of <em>SMAD4</em> in pancreatic cancer has been evaluated in several studies. However, the conclusions remain controversial. Therefore, we aimed to evaluate the prognostic value of the <em>SMAD4</em> gene in pancreatic cancer to aid in the design of therapeutic strategies.</div></div><div><h3>Methods</h3><div>This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and the proposed methodology was registered on PROSPERO. An electronic search was made in MEDLINE (via PubMed), Web of Science and Google Scholar to identify all relevant studies. Eligible studies were those written in English including patients with Pancreatic Ductal Adenocarcinoma (PDAC), who underwent pancreatic surgery with curative intent and provided data on <em>SMAD4</em> gene status or SMAD4 protein expression and its association to prognosis, measured by overall survival (OS). The effect measure of interest was the hazard ratio (HR) for OS between PDAC with or without SMDA4 mutations.</div></div><div><h3>Results</h3><div>A total of 24 studies on <em>SMAD4</em>, with 4340 samples, were included in this systematic review and meta-analysis. Our pooled results demonstrated that patients with tumours with <em>SMAD4</em> alteration had significantly worse prognosis for OS (HR= 1.43, 95% CI = 1.17–1.76, p-value = 0.002).</div></div><div><h3>Conclusion</h3><div>This systematic review and meta-analysis support the use of driver mutations in the <em>SMAD4</em> gene as a prognostic marker for pancreatic cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101091"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study","authors":"Yoshihito Kogure ,&nbsp;Hiroya Hashimoto ,&nbsp;Satoshi Ikeda ,&nbsp;Toshiyuki Harada ,&nbsp;Aoi Hino ,&nbsp;Satoru Miura ,&nbsp;Yasuhiro Goto ,&nbsp;Keiichi Fujiwara ,&nbsp;Nobuyuki Katakami ,&nbsp;Kaoru Kubota ,&nbsp;Naohiko Murata ,&nbsp;Masahide Mori ,&nbsp;Takashi Abe ,&nbsp;Akiko M. Saito ,&nbsp;Nobuyuki Yamamoto ,&nbsp;Hideo Saka ,&nbsp;Masashi Kondo","doi":"10.1016/j.ctarc.2026.101094","DOIUrl":"10.1016/j.ctarc.2026.101094","url":null,"abstract":"<div><h3>Background</h3><div>The CJLSG1901 phase 2 study evaluated efficacy and safety of pembrolizumab plus pemetrexed in older populations. A novel first-line approach for older patients with metastatic non-squamous non-small cell lung cancer (NSCLC) was assessed.</div></div><div><h3>Methods</h3><div>A subgroup analysis was conducted to determine the efficacy and safety of pembrolizumab plus pemetrexed in older patients with metastatic non-squamous NSCLC according to programmed cell death-ligand 1 (PD-L1) status (&lt;1 % vs 1 %–49 %) using data from the CJLSG1901 study.</div></div><div><h3>Results</h3><div>Forty-nine patients were enrolled between July 2020 and May 2022. The objective responserate (ORR) was 36.7 %. The median progression-free survival (PFS) was and median overall survival (OS) were 7.6 months and 19.4 months,respectively. Twenty-one patients had a PD-L1 expression of &lt;1 %, whereas 28 had a PD-L1 expression of 1 %–49 %. The median age, sex, Eastern Clinical Oncology Group performance status, and stage were similar in both groups. ORRs were 23.8 % in the PD-L1 &lt;1 % group and 46.4 % in the PD-L1 1 %–49 % group. Median PFS were 4.4 months in the PD-L1 &lt;1 % group and 7.8 months in the PD-L1 1 %–49 % group. Median OS were 19.4 months and 19.1 months in these groups, respectively. Adverse events (AEs) of any grade were observed in all patients, regardless of PD-L1 status. AE severerity was comparable between the groups. Severe treatment-related AEs occurred in five patients (25 %) in the PD-L1 &lt;1 % group and seven patients (25 %) in the PD-L1 1 %–49 % group.</div></div><div><h3>Conclusions</h3><div>The ORR was higher in the PD-L1 1 %–49 % group; however, the PFS and OS were similar in both groups.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101094"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported satisfaction with thermal water-based cosmetic products in breast cancer patients undergoing chemotherapy: a feasibility study","authors":"Judith Passildas ,&nbsp;Catherine Abrial ,&nbsp;Ioana Molnar ,&nbsp;Marie-Ange Mouret-Reynier ,&nbsp;Joffrey Chalaphy ,&nbsp;Michael Klein ,&nbsp;Xavier Durando","doi":"10.1016/j.ctarc.2026.101168","DOIUrl":"10.1016/j.ctarc.2026.101168","url":null,"abstract":"<div><h3>Aims</h3><div>Chemotherapy and radiotherapy often lead to cutaneous toxicities, which can significantly affect the quality of life of breast cancer patients. Dermatologic side effects of chemotherapy remain an unexplored area of supportive oncology care. This feasibility study aims to assess the patient’s satisfaction and tolerability of thermal water-based cosmetic products for managing chemotherapy-induced skin problems.</div></div><div><h3>Design</h3><div>This prospective, single-center feasibility study included 30 women with non-metastatic breast cancer receiving chemotherapy. Patients were provided with thermal water-based body care products during chemotherapy and spa therapy.</div></div><div><h3>Endpoints</h3><div>Feasibility was assessed by evaluating satisfaction, compliance, and tolerability using visual analogue scales and self-reported questionnaires at the end of chemotherapy (primary) and spa treatment (secondary).</div></div><div><h3>Results</h3><div>At the end of chemotherapy, the mean satisfaction score was 7.52 (<em>n</em> = 23), and after spa treatment, it was 7.15 (<em>n</em> = 13). Compliance rates were 83% during chemotherapy and 54% during spa treatment. Notably, 64% of patients reported improvement in dermatological side effects, including dryness and tightness. Additionally, 69% of patients expressed interest in continuing the use of the products.</div></div><div><h3>Conclusion</h3><div>Thermal water-based cosmetic products demonstrated good satisfaction rate among breast cancer patient with good compliance, tolerability, and moisturizing effects. These findings support the feasibility of the study and suggest a potential benefit of thermal water-based cosmetics in managing chemotherapy-induced skin toxicities. However, these results should be interpreted with caution, as no comparator and no validated dermatologic measures were used. Further studies with robust methodology (i.e., larger sample sizes, comparator and validated dermatologic measures) are needed.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101168"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147385877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}